Biotechnology
TSVT
4.95
price down icon0.40%   -0.02
 

2 Seventy Bio Inc (TSVT)
full-star
loading
Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TSVT? Forum Prognose
Schlusskurs vom Vortag:
$4.97
Offen:
$4.96
24-Stunden-Volumen:
1.31M
Relative Volume:
1.28
Marktkapitalisierung:
$259.07M
Einnahmen:
$44.12M
Nettoeinkommen (Verlust:
$-156.25M
KGV:
-1.6124
EPS:
-3.07
Netto-Cashflow:
$-154.61M
1W Leistung:
+0.00%
1M Leistung:
+90.38%
6M Leistung:
+2.91%
1J Leistung:
-1.20%
1-Tages-Spanne:
Value
$4.93
$4.96
1-Wochen-Bereich:
Value
$4.93
$4.97
52-Wochen-Spanne:
Value
$2.29
$5.90

2 Seventy Bio Inc Stock (TSVT) Company Profile

Name
Firmenname
2 Seventy Bio Inc
Name
Sektor
Healthcare (1162)
Name
Branche
Biotechnology (673)
Name
Telefon
339-499-9300
Name
Adresse
60 BINNEY STREET, CAMBRIDGE
Name
Mitarbeiter
65
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
TSVT's Discussions on Twitter

Vergleichen Sie TSVT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TSVT
2 Seventy Bio Inc
 4.95 259.07M 44.12M -156.25M -154.61M -3.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
 474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
 573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
 555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
 235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
 238.51 25.69B 3.81B -644.79M -669.77M -6.24

2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-06 Herabstufung Goldman Neutral → Sell
2024-01-31 Hochstufung Leerink Partners Market Perform → Outperform
2024-01-31 Herabstufung TD Cowen Outperform → Market Perform
2023-10-30 Herabstufung Leerink Partners Outperform → Market Perform
2023-10-12 Eingeleitet Citigroup Buy
2023-09-13 Herabstufung Goldman Buy → Neutral
2023-09-12 Herabstufung Guggenheim Buy → Neutral
2023-07-28 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-10-31 Eingeleitet Guggenheim Buy
2022-05-02 Eingeleitet Goldman Buy
2022-02-10 Eingeleitet SVB Leerink Outperform
2022-01-06 Eingeleitet Cowen Outperform
2021-11-09 Eingeleitet Canaccord Genuity Buy
2021-11-08 Eingeleitet Morgan Stanley Overweight
2021-11-08 Eingeleitet Wedbush Outperform
Alle ansehen

2 Seventy Bio Inc Aktie (TSVT) Neueste Nachrichten

pulisher
Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Mar 30, 2025
pulisher
Mar 13, 2025

Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma

Mar 13, 2025
pulisher
Mar 13, 2025

2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - Fierce Pharma

Mar 11, 2025
pulisher
Mar 10, 2025

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire

Mar 10, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Mar 10, 2025
pulisher
Mar 06, 2025

2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com

Mar 06, 2025
pulisher
Feb 16, 2025

Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World

Feb 16, 2025
pulisher
Feb 06, 2025

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire

Feb 06, 2025
pulisher
Feb 05, 2025

Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive

Feb 05, 2025
pulisher
Jan 20, 2025

Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World

Jan 20, 2025
pulisher
Jan 04, 2025

Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Jan 04, 2025
pulisher
Dec 18, 2024

Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Dec 18, 2024

Finanzdaten der 2 Seventy Bio Inc-Aktie (TSVT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

2 Seventy Bio Inc-Aktie (TSVT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Baird William D III
President and CEO
Mar 17 '25
Sale
4.95
5,092
25,180
1,121,034
Eatwell Victoria
Chief Financial Officer
Mar 17 '25
Sale
4.95
2,592
12,817
444,387
Kynam Global Healthcare Master
10% Owner
Mar 11 '25
Sale
4.93
11,095,936
54,702,964
0
Kynam Global Healthcare Master
10% Owner
Mar 11 '25
Sale
4.93
5,142,111
25,350,607
0
Snow Jessica
See Remarks
Jan 06 '25
Sale
2.79
5,114
14,289
147,365
Snow Jessica
See Remarks
Jan 03 '25
Sale
2.94
1,000
2,936
152,479
Snow Jessica
See Remarks
Jan 07 '25
Sale
2.64
186
491
147,179
Leschly Nick
Director
Jan 03 '25
Sale
2.94
85,978
252,423
1,234,498
Leschly Nick
Director
Jan 06 '25
Sale
2.78
892
2,478
1,233,606
Eatwell Victoria
Chief Financial Officer
Jan 03 '25
Sale
2.94
1,013
2,974
339,076

Ähnlich wie TSVT

biotechnology INCY
$60.58
price down icon 3.01%
biotechnology INSM
$69.18
price down icon 5.66%
biotechnology SMMT
$17.36
price down icon 8.20%
biotechnology RPRX
$31.11
price down icon 2.14%
biotechnology BNTX
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters
Kapitalisierung:     |  Volumen (24h):